C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 6.3 USD -9.74% Market Closed
Market Cap: 105.4m USD

EV/EBIT
Enterprise Value to EBIT

-3.3
Current
-3.8
Median
6.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.3
=
Enterprise Value
75.6m USD
/
EBIT
-22.6m USD
EBIT Growth EV/EBIT to Growth
US
C
Coya Therapeutics Inc
NASDAQ:COYA
Average EV/EBIT: 30.4
Negative Multiple: -3.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 853.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.5
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
15.2
13%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
17%
1.4
AU
CSL Ltd
ASX:CSL
18.4
14%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14
12%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -326.7 N/A N/A
NL
argenx SE
XBRU:ARGX
98.6
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.8
2-Years Forward
EV/EBIT
-2.2
3-Years Forward
EV/EBIT
-2.6